Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
Healthcare
$18.31 +0.58%
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
52W Low $14.85High $23.00
Volume 0.68M
Average 0.41M
SPTX Net Income
Bottom-line profit after all expenses, interest, and taxes.
No reported Net Income figures are available to summarize.
Net Income history
Currency unavailable · from the income statement
No Net Income data reported for this period type.
Net Income vs competitors
How SPTX compares with its peers on the latest reported figures
SPTX Competitors
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$39.17M USD | — | — | — |
| LTM Mar 2026 | -$56.41M USD | -34.0% | — | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | -$58.44M USD | -17.3% | — | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$107.28M USD | -34.6% | — | 536.4% |
| LTM Mar 2026 | -$199.48M USD | -146.3% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$222.39M USD | +13.8% | — | — |
| LTM Mar 2026 | -$239.55M USD | -441.4% | — | 110.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | -34.3% | — | 323.2% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Currency unavailable
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.